These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15606417)

  • 1. Analysis of times to repeated events in two-arm randomized trials with noncompliance and dependent censoring.
    Matsui S
    Biometrics; 2004 Dec; 60(4):965-76. PubMed ID: 15606417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administrative and artificial censoring in censored regression models.
    Joffe MM
    Stat Med; 2001 Aug; 20(15):2287-304. PubMed ID: 11468764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    Biom J; 2007 Aug; 49(4):613-26. PubMed ID: 17634977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Bayesian adaptive randomization based on event times with covariates.
    Cheung YK; Inoue LY; Wathen JK; Thall PF
    Stat Med; 2006 Jan; 25(1):55-70. PubMed ID: 16025549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of statistical methods for analysing survival data in the presence of non-random compliance.
    Odondi L; McNamee R
    Stat Med; 2010 Dec; 29(29):2994-3003. PubMed ID: 20963732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint analysis of longitudinal data with informative right censoring.
    Liu M; Ying Z
    Biometrics; 2007 Jun; 63(2):363-71. PubMed ID: 17425632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study).
    Yoshida M; Matsuyama Y; Ohashi Y;
    Clin Trials; 2007; 4(4):318-28. PubMed ID: 17848493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials.
    Wahed AS; Tsiatis AA
    Biometrics; 2004 Mar; 60(1):124-33. PubMed ID: 15032782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regarding paper "Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance" by Lui K. J. and Chang K. C.
    Vach W
    Biom J; 2007 Aug; 49(4):627-9; author reply 630-1. PubMed ID: 17722194
    [No Abstract]   [Full Text] [Related]  

  • 10. One- and two-sample nonparametric inference procedures in the presence of a mixture of independent and dependent censoring.
    Park Y; Tian L; Wei LJ
    Biostatistics; 2006 Apr; 7(2):252-67. PubMed ID: 16282531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
    Wang H; Zhao H
    Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trials for the real world: making as few and as reasonable assumptions as possible.
    Baker SG; Kramer BS
    Stat Methods Med Res; 2008 Jun; 17(3):243-52. PubMed ID: 17925312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects.
    Yamaguchi T; Ohashi Y
    Stat Med; 2004 Jul; 23(13):1991-2003. PubMed ID: 15211598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An extended general location model for causal inferences from data subject to noncompliance and missing values.
    Peng Y; Little RJ; Raghunathan TE
    Biometrics; 2004 Sep; 60(3):598-607. PubMed ID: 15339281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximum likelihood estimation in survival studies under progressive interval censoring with random removals.
    Xiang L; Tse SK
    J Biopharm Stat; 2005; 15(6):981-91. PubMed ID: 16279356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death.
    Cain LE; Cole SR
    Stat Med; 2009 May; 28(12):1725-38. PubMed ID: 19347843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interval estimation of the risk difference in non-compliance randomized trials with repeated binary measurements.
    Lui KJ
    Stat Med; 2007 Jul; 26(16):3140-56. PubMed ID: 17177272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regularized estimation in the accelerated failure time model with high-dimensional covariates.
    Huang J; Ma S; Xie H
    Biometrics; 2006 Sep; 62(3):813-20. PubMed ID: 16984324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment.
    Walker AS; White IR; Babiker AG
    Stat Med; 2004 Feb; 23(4):571-90. PubMed ID: 14755390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.